Amylin Pharmaceuticals
 |
|
| Type | Public (NASDAQ: AMLN) |
|---|---|
| Founded | 1987 |
| Headquarters |  San Diego, California, USA |
| Key people | Daniel M. Bradbury[1] |
| Industry | Biotechnology |
| Products | Symlin (pramlintide) Byetta (exenatide) |
| Market cap | 1.7 billion USD[1] |
| Employees | 1,900 [1] |
| Website | www.amylin.com |
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin.[2] Amylin is part of the NASDAQ-100.
References
Categories: Companies listed on NASDAQ | Companies in the NASDAQ-100 Index | Pharmaceutical companies | Companies in the NASDAQ Biotechnology Index | Companies based in San Diego, California
Hidden category: Portal:Companies/Total
Why are we here?
All text is available under the terms of the GNU Free Documentation License
This page is cache of Wikipedia. History